Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered ...

当自身免疫反应发生时，辅助T细胞无法正确区分外来抗原和自身肽段，因此无论如何都会发起攻击。为了防止这种情况发生，另一组被称为CD4+调节性T细胞（Treg）的T细胞应该进行干预，防止Tconv细胞的友军误伤。

他们的研究成果发表在《Cell Death and Disease》杂志上 ... 详细阐述了免疫细胞的分子特征和细胞间通信模式。研究发现 I 期 HGSOC 中 Treg 细胞具有高度异质性，其在肿瘤早期生长中发挥着重要作用。同时，研究还指出 IFNγ 信号可能是 Treg 细胞不稳定的驱动因素 ...

该研究系统性阐释了非小细胞肺癌患者在新辅助免疫治疗联合化疗后的免疫微环境异质性，识别了患者在耐药机制方面的潜在差异，并开发了预测患者复发风险的新型生物学标志物，具有一定的基础研究与临床转化价值。

2025年3月26日，上海市肺科医院陈昶教授与北京大学生物医学前沿创新中心张泽民院士等合作团队，在国际期刊Cell上以Resource形式在线发表了题为“A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer” 的研究论文。陈昶教授及胸外科佘云浪副研究为该论文的 ...

Skin microbes do more than coexist—they shape immune responses, repair tissue, and influence gene expression across your ...

To prevent this from happening, another group of T cells called CD4+ regulatory T (Treg) cells, are supposed to intervene and prevent friendly fire from the Tconv cells. "You can think of them ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 20.19%, which has investors questioning if this is right time to ...